Role of Gastric Acid Suppression Therapy in Erosive Esophagitis: From H2 Receptor Antagonists, Proton Pump Inhibitors, to Potassium-Competitive Acid Blockers
Keywords:
Proton pump inhibitor, Histamine-2 receptor antagonist , Potassium-competitive acid blockers , erosive esophagitis, gastroesophageal reflux diseaseAbstract
Erosive esophagitis (EE) is an inflammation of the esophageal mucosa resulting from gastric and duodenal acid reflux, affecting approximately 55% of gastroesophageal reflux disease (GERD) patients in Indonesia. Effective acid suppression is essential for mucosal healing and symptomatic relief. Histamine-2 receptor antagonist (H2RA) was initially used for standard treatment for GERD, including EE, reducing gastric acid secretion by blocking H2 receptors. However, their efficacy is limited by inadequate acid suppression. Proton pump inhibitors (PPIs) became the mainstay therapy due to their stronger and longer-lasting acid suppression. Although PPIs have been proven to be quite effective, they have several limitations, including slow onset and inability to provide sustained acid suppression over a full 24-hour period. In recent years, Potassium-competitive acid blockers (PCAB) have become known as a category of drugs that effectively suppress gastric acid production, through a slightly different mechanism, and have advantages over PPIs, including faster onset and longer time of action. Both PPIs and PCABs can be used as therapy for patients with EE. PCABs are more recommended, especially in patients with severe grades of EE. H2RAs may still be considered in patients who have already received PPI therapy but continue to experience unresolved nocturnal acid symptoms.References
Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal reflux disease. JAMA. 2020;324(24).
Witarto AP, Witarto BS, Pramudito SL, et al. Risk factors and 26-year worldwide prevalence of endoscopic erosive esophagitis from 1997 to 2022: a meta-analysis. Sci Rep. 2023;13(1).
Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018. Gastroenterology. 2019;156.
Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis. World Journal of Gastroenterology. 2005;11.
Herardi R, Syam AF, Simadibrata M, et al. Comparison of a 10-day course of triple therapy versus a 14-day course for eradication of Helicobacter pylori infection in an Indonesian population: Double-blinded randomized clinical trial. Asian Pacific Journal of Cancer Prevention. 2020;21(1).
Xiao YL, Zhou LY, Hou XH, Li YQ, Zou DW, Chen MH. Chinese expert consensus on gastroesophageal reflux disease in 2020. J Dig Dis. 2021;22(7).
Abdel-Aziz Y, Metz DC, Howden CW. Review article: Potassium-competitive acid blockers for the treatment of acid-related disorders. Alimentary Pharmacology and Therapeutics. 2021;53.
Fass R, Frazier R. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therapeutic Advances in Gastroenterology. 2017;10.
Syam AF, Hapsari PF, Makmun D. The prevalence and risk factors of GERD among Indonesian medical doctors. Makara Journal of Health Research. 2016;20(2).
Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: A meta-analysis. Gut. 2018;67(3).
Argyrou A, Legaki E, Koutserimpas C, et al. Risk factors for gastroesophageal reflux disease and analysis of genetic contributors. World Journal of Clinical Cases. 2018;6.
Hershcovici T, Fass R. Nonerosive Reflux Disease (NERD) - An Update. J Neurogastroenterol Motil. 2010;16(1).
Kandulski A, Weigt J, Caro C, Jechorek D, Wex T, Malfertheiner P. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn. Clinical Gastroenterology and Hepatology. 2015;13(6).
Indonesian Society of Gastroenterology. Konsensus nasional penatalaksanaan penyakit refluks gastroesofagea. Jakarta: PIP Interna; 2022.
Moon SH. Sedation regimens for gastrointestinal endoscopy. Clin Endosc. 2014;47(2):135–40.
Dunbar KB, Agoston AT, Odze RD, et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA - Journal of the American Medical Association. 2016;315(19).
Herregods TVK, Bredenoord AJ, Smout AJPM. Pathophysiology of gastroesophageal reflux disease: New understanding in a new era. Neurogastroenterology and Motility. 2015;27.
Satta PU, Oppia F, Cabras F. Overview of pathophysiological features of GERD. Minerva Gastroenterologica e Dietologica. 2017;63.
S, Simadibrata M. Diagnosis and treatment of refractory gastroesophageal reflux disease (GERD). The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy. 2015;16(3).
Naik RD, Vaezi MF. Extra-esophageal gastroesophageal reflux disease and asthma: Understanding this interplay. Expert Review of Gastroenterology and Hepatology. 2015;9.
Zavala-Gonzáles MA, Azamar-Jacome AA, Meixueiro-Daza A, et al. Validation and diagnostic usefulness of the gastroesophageal reflux disease questionnaire in the primary care level in Mexico. J Neurogastroenterol Motil. 2014;20(4).
Siahaan B, Arles A, Azhari W. Relationship between GERD-Q score with esophagitis findings in endoscopy. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy. 2020;21(3).
Simarmata DO, Wahyudi Y, Bestari MB, Supriadi R. Relationship between gastroesophageal reflux disease questionnaire (GERD-Q) score and reflux oesophagitis in gastroesophageal reflux disease (GERD) suspected patients in Bandung. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy. 2020;20(3).
Genta RM, Spechler SJ, Kielhorn AF. The Los Angeles and Savary-Miller systems for grading esophagitis: Utilization and correlation with histology. Diseases of the Esophagus. 2011;24(1).
Fock KM, Talley N, Goh KL, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: An update focusing on refractory reflux disease and Barrett’s oesophagus. Gut. 2016;65(9).
Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022;117(1).
Perkumpulan Gastroenterologi Indonesia (PGI). Konsensus nasional penatalaksanaan penyakit refluks gastroesofageal (gastroesophageal reflux disease/GERD) di Indonesia (revisi 2022). Jakarta: PIP Interna; 2022.
Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24(2).
Meng R, Chen LR, Zhang ML, et al. Effectiveness and safety of histamine H2 receptor antagonists: An umbrella review of meta-analyses. Journal of Clinical Pharmacology. 2023;63.
McRorie JW, Kirby JA, Miner PB. Histamine 2 -2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014;5(2).
Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology. 2018 Jan 1;154(2):302–18.
Kalaitzkasis E, Björnsoson E. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Therapeutics and Clinical Risk Management. 2007;3.
Pilotto A, Franceschi M, Leandro G, et al. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol. 2007;13(33).
Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol. 2009;15(8).
Wong N, Reddy A, Patel A. Potassium-competitive acid blockers: Present and potential utility in the armamentarium for acid peptic disorders. Gastroenterol Hepatol (N Y). 2022;18(12).
Hwang JG, Yoo H, Lee JW, Song GS, Lee S, Kim MG. Comparison of pharmacokinetic characteristics of two tegoprazan (CJ-12420) formulations in healthy male subjects. Transl Clin Pharmacol. 2019;27(2).
Lee JW, Kim N, Nam RH, et al. Efficacy of Tegoprazan for improving the susceptibility of antimicrobial agents against antibiotic-resistant Helicobacter pylori. Gut Liver. 2021;15(1).
Xu W, Bai Z, Shang Y, Wang J, Wong Y, Qi X. Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis. Therap Adv Gastroenterol. 2023;16.
Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2).
Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: A dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42(6).
Laine L, DeVault K, Katz P, et al. Vonoprazan Versus Lansoprazole for healing and maintenance of healing of erosive esophagitis: A randomized trial. Gastroenterology. 2023;164(1).
Xiao Y, Zhang S, Dai N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69(2).
Lee KJ, Son BK, Kim GH, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(7).
Cho YK, Kim JH, Kim HS, et al. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther. 2023;57(1).
Sakurai K, Suda H, Fujie S, et al. Short-term symptomatic relief in gastroesophageal reflux disease: A comparative study of esomeprazole and vonoprazan. Dig Dis Sci. 2019;64(3).
Visaggi P, Del Corso G, Gyawali CP, et al. Ambulatory pH-impedance findings confirm that grade B esophagitis provides objective diagnosis of gastroesophageal reflux disease. American Journal of Gastroenterology. 2023;118(5).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ryan Herardi, Ari Fahrial Syam, Achmad Fauzi, Ikhwan Rinaldi, Sharon Sandra, Anisya Zakiyyahaya Arvant
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
